Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price fell 1% on Wednesday . The stock traded as low as C$4.05 and last traded at C$4.14. 9,455 shares were traded during trading, an increase of 28% from the average session volume of 7,410 shares. The stock had previously closed at C$4.18.
Eupraxia Pharmaceuticals Stock Performance
The firm has a 50 day moving average of C$3.43 and a two-hundred day moving average of C$3.08.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Quiet Period Expirations Explained
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
